ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,464.62
-0.16%
Dow Jones
39,150.33
0.04%
US Dollar vs MXN
18.1108
0.00%
Brent Oil
84.39
0.00%
Bitcoin
64,452.49
0.32%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. bioAffinity Technologies Inc (BIAFW)

  7. bioAffinity Technologies Inc (BIAFW) Noticias

BIAFW

bioAffinity Technologies (BIAFW)

bioAffinity Technologies Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:BIAFW
FechaHoraFuenteTítuloSímboloCompañía
14/06/202419:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIAFWbioAffinity Technologies Inc
12/06/202407:00Business WirebioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung TestsNASDAQ:BIAFWbioAffinity Technologies Inc
05/06/202415:30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BIAFWbioAffinity Technologies Inc
05/06/202415:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIAFWbioAffinity Technologies Inc
22/05/202415:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:BIAFWbioAffinity Technologies Inc
15/05/202409:53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BIAFWbioAffinity Technologies Inc
15/05/202408:15Business WirebioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory VolumesNASDAQ:BIAFWbioAffinity Technologies Inc
02/05/202407:00Business WirebioAffinity Technologies News UpdateNASDAQ:BIAFWbioAffinity Technologies Inc
24/04/202407:00Business WirebioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of GrowthNASDAQ:BIAFWbioAffinity Technologies Inc
09/04/202407:00Business WirebioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer ScreeningNASDAQ:BIAFWbioAffinity Technologies Inc
01/04/202408:49Business WirebioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:BIAFWbioAffinity Technologies Inc
08/03/202411:45Business WirebioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:BIAFWbioAffinity Technologies Inc
06/03/202408:46Business WirebioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:BIAFWbioAffinity Technologies Inc
30/01/202407:00Business WirebioAffinity Technologies In The NewsNASDAQ:BIAFWbioAffinity Technologies Inc
08/01/202407:00Business WirebioAffinity Technologies In the NewsNASDAQ:BIAFWbioAffinity Technologies Inc
05/12/202307:00Business WirebioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of DirectorsNASDAQ:BIAFWbioAffinity Technologies Inc
30/11/202307:00Business WireCMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024NASDAQ:BIAFWbioAffinity Technologies Inc
28/11/202307:00Business WirebioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology PostNASDAQ:BIAFWbioAffinity Technologies Inc
14/11/202315:01Business WirebioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BIAFWbioAffinity Technologies Inc
06/11/202307:00Business WirebioAffinity Technologies Names Dallas J. Coleman as National Director of SalesNASDAQ:BIAFWbioAffinity Technologies Inc
10/10/202307:00Business WirebioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth ConferenceNASDAQ:BIAFWbioAffinity Technologies Inc
07/09/202307:00Business WirebioAffinity Technologies to Participate in the H.C. Wainwright Global Investment ConferenceNASDAQ:BIAFWbioAffinity Technologies Inc
14/08/202316:03Business WirebioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BIAFWbioAffinity Technologies Inc
12/07/202307:00Business WireAMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung CancerNASDAQ:BIAFWbioAffinity Technologies Inc
15/06/202307:00Business WirebioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics SymposiumNASDAQ:BIAFWbioAffinity Technologies Inc
22/05/202307:00Business WirebioAffinity Technologies Presents Research Findings at CYTO 2023NASDAQ:BIAFWbioAffinity Technologies Inc
01/05/202307:00Business WirebioAffinity Technologies Names Michael Dougherty as Chief Financial OfficerNASDAQ:BIAFWbioAffinity Technologies Inc
25/04/202307:00Business WirebioAffinity Technologies Presents at Cleveland Clinic Lung Cancer SymposiumNASDAQ:BIAFWbioAffinity Technologies Inc
31/03/202316:52Business WirebioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial ResultsNASDAQ:BIAFWbioAffinity Technologies Inc
 Showing the most relevant articles for your search:NASDAQ:BIAFW

Su Consulta Reciente

BTRX
MIMUSDT
Mint Marble
BIT
P1S0V7
NLBNPIT1S0V7 20241220 22
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados